ARTICLE | Finance
Ausperbio, Gemmabio, Velavigo tap VCs for cash in late December
In BioCentury’s latest Venture Report, two trans-Pacific companies and a gene therapy newco draw funding
January 3, 2025 10:47 PM UTC
Although the holiday season slowed the pace of VC deals to a trickle, internationally-focused biotechs Ausperbio, Velavigo and Gemmabio each announced new venture rounds in the waning days of 2024.
Ausperbio Therapeutics Inc., a start-up with operations in California and China, announced a $73 million series B round that will drive continued clinical work on its potentially curative antisense therapy for chronic HBV infection. The treatment, derived from its Multi-segmented Enhanced and Dual-acting Oligonucleotides (Med-Oligo) platform, is in Phase II testing in China. Ausperbio said the funds will support clinical trials both in China and elsewhere around the globe...